FANCG was the third Faconi anaemia gene identified and proved to be identical to the previously cloned XRCC9 gene. We present the pathogenic mutations and sequence variants we have so far identified in a panel of FA-G patients. Mutation screening was performed by PCR, single strand conformational polymorphism analysis and protein truncation tests. Altogether 18 mutations have been determined in 20 families -97% of all expected mutant alleles. All mutation types have been found, with the exception of large deletions, the large majority is predicted to lead to shortened proteins. One stop codon mutation, E105X, has been found in several German patients and this founder mutation accounts for 44% of the mutant FANCG alleles in German FA-G patients. Comparison of clinical phenotypes shows that patients homozygous for this mutation have an earlier onset of the haematological disorder than most other FA-G patients. The mouse Fancg sequence was established in order to evaluate missense mutations. A putative missense mutation, L71P, in a possible leucine zipper motif may affect FANCG binding of FANCA and seems to be associated with a milder clinical phenotype.
Introduction
The autosomal recessive genetic disorder Fanconi anaemia (FA; MIM 227650) is genetically highly heterogeneous with seven complementation groups so far established and thus seven causative genes anticipated 1 (Joenje et al 2000, personal communication) . The identification of these genes is an important goal for understanding the pathophysiology of the disease since the basic defect is still poorly understood.
The characteristic chromosomal breakage observed in patient cells, particularly after treatment with a bifunctional alkylating agent capable of forming DNA interstrand crosslinks, has led to the assumption that FA cells are deficient in the repair of this DNA lesion. However, alternative theories implicating cell cycle regulation, oxygen detoxification and apoptosis have been proposed. 2, 3 The clinical picture of FA is characterised by progressive bone marrow failure and an increased risk of neoplasia, particularly leukemia. In addition, a range of variable congenital defects such as growth retardation, skeletal abnormalities including radial aplasia and hyperpigmentation of the skin are observed in some patients. 4 Whilst increased chromosomal breakage remains the critical diagnostic test for FA, recent studies have demonstrated reverse mosaicism in FA leading to a population of undamaged cells in peripheral blood lymphocytes. 5, 6 Of the seven FA genes, four have been identified: FANCA, 7, 8 FANCC, 9 FANCF 10 and FANCG. 11 The localisation of FANCG on chromosome 9p13 was established by homozygosity mapping and linkage analysis in FA-G families, 12 its identification was achieved by functional complementation of FA-G lymphoblastoid cells after cDNA transfer. 11 The gene thus identified was identical to XRCC9, localised on 9p13, and previously identified by virtue of its ability to complement a crosslinker sensitive hamster cell mutant, UV40.
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The gene covers some 6 kb with 14 exons and has a 2.5 kb mRNA encoding the FANCG protein of 622 amino acids and a calculated molecular weight of 68 kD. The protein shows no homology to known proteins and its function is thus unclear. However, several studies have shown that FANCG is found in the cells as a nuclear complex with the FANCA protein. 14, 15 Pathogenic mutations in FANCG were previously reported in four FA-G patients, we report here further mutations in 16 FA-G patients, including common German and Turkish founder mutations.
Materials and methods

Patients and samples
Patients were diagnosed on the basis of chromosomal breakage tests and clinical features. Many patients were recruited as part of the European Concerted Action on FA Research (EUFAR), others were referred to the contributing laboratories for diagnosis. Clinical data were collected on a standard EUFAR questionnaire. Where possible, lymphoblastoid cell lines were established by EBV transformation and fused to the 7 FA reference cell lines to establish complementation group. 1, 16 In some cases, assignment to FA group G was indicated by the absence of detectable FANCG protein in immunoblots. DNA and RNA were extracted from LCLs and/or peripheral blood samples by standard techniques.
Mutation screening
Mutations in the FANCG gene were screened by amplification of all 14 exons from genomic DNA, using primers flanking the exon/intron boundaries as described previously, 11 or by amplification of FANCG cDNA from RNA. SSCP analysis under four different conditions was used to identify exon PCR products with an aberrant mobility pattern; bis-acrylamide:acrylamide ratios of 1:30 and 1:50, gel runs at 4°C and at 15°C. Fragments showing an aberrant SSCP pattern were sequenced using the ABI 310 (Foster City, CA, USA) sequencer to identify the mutations. Most patients showed mobility shifts in one or more exons, those mutant alleles not detectable by SSCP were sequenced directly. Some patient samples were screened by RT-PCR and in vitro translation using standard methods. 17 Appropriate FANCG exons were then amplified and sequenced to establish the underlying mutation.
Where possible, the identified mutations were confirmed by restriction enzyme digest of appropriate PCR products bearing the mutation, by RT-PCR and/or by examination of DNA from the patients' parents.
Mouse Fancg sequence A BLAST v2.0 search with the entire FANCG cDNA sequence revealed high homology (P = 7e-37) to an anonymous murine BAC clone in the GenBank database (Lamerdin et al, accession no. AC005259). The murine coding sequence was verified by the amplification of the Fancg cDNA from mouse total RNA by nested RT-PCR using specific primers. The amplified product was 1.9 kb long, in agreement with estimates for the size of the Fancg transcript encoded by the BAC clone. The RT-PCR product was sequenced and the completed Fancg cDNA sequence has been submitted to GenBank with accession number AF112439.
Haplotype analysis at the FANCG locus Examination of the sequence of the P1 clone, 11659 (Lamerdin et al, accession no. AC004472), containing the entire FANCG gene revealed the presence of a (CA) dinucleotide repeat at position 5531 of the clone, 48 kb from the 3' end of the FANCG coding sequence. Primers were designed which flank this repeat and 65 unrelated individuals were examined for polymorphism in the size of the CA repeat sequence; 81% of the individuals were heterozygous. This genetic marker has been given the assignment D9S2176.
DNAs from families in which the common 313G → T or 1649delC mutations segregate were examined for microsatellite markers D9S2176, D9S1853, D9S1874, D9S1817, and D9S165 located at the FANCG locus. PCR products were analysed on Pharmacia ALF (Freiburg, Germany) sequencing apparatus. Table 1 details the FANCG mutations found in the 16 new FA-G patients examined here and for the four patients previously described. 11 The majority of mutated alleles (94%) are expected to result in protein truncation. Six mutations are small deletions (1, 2, or 10 bp) or insertions (2 bp) leading to frame shifts and premature termination of translation after, between 4 and 81 novel codons. Six mutations affect the invariable intronic bases of mRNA splice sites (donor sites of introns 2, 5 and 11; acceptor sites of introns 8, 9 and 13), and would be predicted to result in false splicing, frame shift and truncated proteins. The loss of exon 2 due to the IVS-2 + 1G → A mutation in patient FA1BER was verified by RT-PCR and sequencing ( Figure 1 ). Interestingly, the second mutant allele, which has a dinucleotide deletion in exon 4, was not detectable in this RT-PCR, suggesting that the The splice mutation IVS8-2A → G leads to two aberrant mRNAs. One RNA species has exon 8 joined to exon 10, as expected if the acceptor of intron 8 is inactivated. This is predicted to result in protein truncation after 20 amino acids. The other RNA has exon 8 joined to a cryptic acceptor site, 25 bases into exon 10, leading to truncation after two amino acids (data not shown).
Results
Four base change mutations lead to premature stop codons, in exon 4, exon 6 and exon 13, but only one missense mutation has been found so far. The transition 212T → C, for which the patient EUFA569 is homozygous, leads to the non-conservative amino acid substitution of proline for leucine at position 71. This mutation was not found in 100 ethnically matched chromosomes and no other sequence variation was found in this patient's DNA. Examination of the mouse cDNA sequence presented here (Figure 2) shows that the amino acid leucine is conserved at this position in the mouse sequence. The 18 mutations found so far show no obvious clustering within the gene (Figure 3) .
Three sequence variants, all affecting amino acid coding, were found in the FANCG gene of FA-G patients. These are not considered to be disease related, since in each case a truncating mutation was found in the same allele. Analysis of 100 ethnically matched chromosomes resulted in the frequencies for these polymorphisms given in Table 2 . The base change, 77A → G, leading to Q26R was not found in 70 ethically matched chromosomes and affects an amino acid conserved in the mouse sequence; however, it does not disturb complementation of Mitomycin C sensitivity after transfection into FA-G cells (data not shown) and thus presumably represents a rare variant.
As with other FA genes, most mutations have been found only once. However, the truncating mutation, 313G → T, was found in six of nine unrelated German patients examined. Of the 18 alleles expected among these German patients, eight carry 313G → T. Analysis of microsatellite markers linked to FANCG indicated a common ancestral haplotype on which the 313G → T mutation occurred ( Table 3 ). The most tightly linked markers, D9S2176 (approximately 50 kb from FANCG) and D9S1817 each have the same size repeat on the mutant haplotype in all patients. The D9S2176 allele 335 bp has a population frequency of 0.038. D9S1853 and D9S165 have the same alleles in most patients but also show evidence of haplotype erosion due to mutation and/or recombination. The transversion 313G → T thus represents a common FANCG founder mutation in Germany. A further common mutation among German patients is the 10 bp deletion, 1183-1192del. This is present only together with the sequence variant 1182T → C, not found among 100 matched chromosomes (data not shown), thus indicating a common origin.
Evidence for a founder chromosome among Turkish patients is given by two patients homozygous for the deletion 1649delC. Again there is a common haplotype at D9S2176 (327 bp) and D9S1817 (267 bp) in these patients (data not shown). These patients also share the sequence variant, S7F (Table 2) . 
FANCG/XRCC9 gene mutations I Demuth et al y
The phenotypes of 23 of the patients for whom FANCG mutations have been established here are given in a standardised format for a selection of particularly common clinical features in Table 4 . The heterogeneity characteristic for FA is clearly demonstrated, even the sibling pairs show discordance for several symptoms. The average age of haematological onset in this group of patients is 6.1 years (range 0 to 15 years), not significantly different from that found in other FA complementation groups (Faivre et al, 2000 personal communication); growth retardation and café au lait spots are common (78% and 75% of patients, respectively). Thumb malformations and microphthalmia are present in less than half the patients (36% and 36%, respectively).
Discussion
Mutation analysis by SSCP of amplified exons has proved to be highly efficient for detection of mutations in FANCG. In the 20 patients screened for mutations in the FANCG/XRCC9 gene, a total of 18 different mutations which are likely to be pathogenic were identified. Of these, > 90% were initially detected by SSCP or similar indirect methods. Thirteen of the patients proved to have homozygous mutations and this was expected in seven of these, due to consanguinity. For the compound heterozygous patients, only one mutation could not be determined, although this allele is expressed at the mRNA level as shown by RT-PCR (data not shown). This equates to a detection rate of 97% using the methodology described here, contrasting strongly with the situation in FANCA, where frequent partial deletions make mutation analysis difficult. 18, 19 The majority of the mutations described are expected to yield truncated FANCG proteins varying from 7% to 95% of the wild type 68 kD. FANCG is known to form a complex with FANCA, and it has been shown that this binding is due to sequences both in the amino terminal and the carboxy terminal ends of the protein 20 Only one missense mutation has been found and its physiological relevance is revealed by comparison with the mouse cDNA sequence presented here. A comparison of the Fancg sequence with that of FANCG is shown in Figure 2 . The two orthologues show 71.8% identity and 88% similarity at the amino acid level. Direct comparison of the murine and human protein sequences allows the identification of totally conserved and conservatively substituted residues which might be essential for biological function. Attention has been drawn to leucine zipper motifs in the FANCA and FANCG proteins. 7, 8, 13 In the case of murine Fancg, this motif (a heptad repeat of leucine residues of the form L-X 6 -L) is not totally conserved (Figure 2) . Interestingly, the murine protein also contains another shorter leucine zipper motif from residues 58-79 which is not totally conserved in the human protein.
The missense mutation L71P in patient EUFA569 is located directly in the second putative leucine zipper at a conserved leucine residue. Substitution of leucine by proline 14 Of 35 assigned German families, nine belong to complementation group FA-G making this the second largest group in Germany after FA-A (68%). The 313G → T mutation accounts for 44% of the alleles in German FA-G patients and is clearly due to a founder effect. Whilst there is generally no clear correlation between the mutations described here and the clinical symptoms, the two patients homozygous for the common 313G → T mutation do show a relatively early onset of the haematological disorder at 1.4 and 2.4 years in comparison with an average of 6.1 years for the 23 FA-G patients as a whole (Table 4 ). The putative missense L71P mutation found in patient EUFA569 would seem to lead to a disease with later onset (13 years) and milder clinical course. This patient is currently haematologically healthy at 26 years of age. The founder mutation, 1649delC, among Turkish patients is not obviously associated with a particular clinical phenotype.
One of the patients described here, FA1BER, was originally diagnosed with Estren Dameshek anaemia, considered to be a subtype of FA without malformations. 21, 22 However, this patient has mutations in the FANCG gene as do other patients with a more classical phenotype. There is, therefore, no genetic basis for the Estren Dameschek subtype. Fibroblasts from the patient FA1BER, which would have, if at all, a truncated FANCG protein of 4.6 kD, have been examined extensively in various laboratories and have been shown to have several biochemical defects. Analysis of psoralen interstrand DNA crosslinks in these cells using isopyknic centrifugation of denatured genomic DNA provided one of the few demonstrations of a crosslink removal defect in Fanconi anaemia. 23 Persisting DNA crosslinks are expected to prevent semiconservative DNA replication, and indeed a permanently reduced DNA synthesis rate after a crosslinking treatment has been shown for these cells. 24 Nevertheless, the repair of UV-induced thymine dimers is normal in these cells, 25 reflecting the fact that lesions affecting just one DNA strand are repaired by the independent pathways of baseexcision and nucleotide-excision repair. D9S1853  249  249  249  249  251  261  257  53.60  D9S165  212  212  212  212  212  212  216  58.26  D9S2176  335  335  335  335  335  335  335  D9S1817  257  257  257  257  257  257  257  59.34  D9S1874  195  195  195  197  197  197  195  61.38 Sizes of PCR products containing (CA)n repeats at the listed loci are given in bp; a Genetic distance in cM from 6pter taken from the Marshfield Medical Research Foundation (http://www.marshmed.org/genetics/). Conserved alleles are shaded. 
